GSK details Blenrep’s PhIII combo win as it hopes to stage a turnaround in multiple myeloma

GSK’s Blenrep in com­bi­na­tion with two oth­er med­i­cines cut the risk of dis­ease pro­gres­sion or death by 59% com­pared to a stan­dard com­bi­na­tion for mul­ti­ple myelo­ma, the phar­ma com­pa­ny an­nounced Mon­day evening.

The study is part of GSK’s bid to bring the can­cer med­i­cine back to mar­ket af­ter yank­ing it from the US in 2022 when a con­fir­ma­to­ry tri­al failed. It had been grant­ed an ac­cel­er­at­ed ap­proval in 2020, though it was on­ly la­beled for a nar­row group of pa­tients and didn’t gen­er­ate ma­jor sales at the time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.